These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

312 related items for PubMed ID: 20422343

  • 1. Disruption of p73-MDM2 binding synergizes with gemcitabine to induce apoptosis in HuCCT1 cholangiocarcinoma cell line with p53 mutation.
    Zheng T, Wang J, Chen X, Meng X, Song X, Lu Z, Jiang H, Liu L.
    Tumour Biol; 2010 Aug; 31(4):287-95. PubMed ID: 20422343
    [Abstract] [Full Text] [Related]

  • 2. Nutlin-3 cooperates with doxorubicin to induce apoptosis of human hepatocellular carcinoma cells through p53 or p73 signaling pathways.
    Zheng T, Wang J, Song X, Meng X, Pan S, Jiang H, Liu L.
    J Cancer Res Clin Oncol; 2010 Oct; 136(10):1597-604. PubMed ID: 20174822
    [Abstract] [Full Text] [Related]

  • 3. Mdm2 inhibition induces apoptosis in p53 deficient human colon cancer cells by activating p73- and E2F1-mediated expression of PUMA and Siva-1.
    Ray RM, Bhattacharya S, Johnson LR.
    Apoptosis; 2011 Jan; 16(1):35-44. PubMed ID: 20812030
    [Abstract] [Full Text] [Related]

  • 4. MDM2 antagonist can inhibit tumor growth in hepatocellular carcinoma with different types of p53 in vitro.
    Wang J, Zheng T, Chen X, Song X, Meng X, Bhatta N, Pan S, Jiang H, Liu L.
    J Gastroenterol Hepatol; 2011 Feb; 26(2):371-7. PubMed ID: 21261729
    [Abstract] [Full Text] [Related]

  • 5. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function.
    Lau LM, Nugent JK, Zhao X, Irwin MS.
    Oncogene; 2008 Feb 07; 27(7):997-1003. PubMed ID: 17700533
    [Abstract] [Full Text] [Related]

  • 6. Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21).
    Drakos E, Singh RR, Rassidakis GZ, Schlette E, Li J, Claret FX, Ford RJ, Vega F, Medeiros LJ.
    Leukemia; 2011 May 07; 25(5):856-67. PubMed ID: 21394100
    [Abstract] [Full Text] [Related]

  • 7. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
    Ambrosini G, Sambol EB, Carvajal D, Vassilev LT, Singer S, Schwartz GK.
    Oncogene; 2007 May 24; 26(24):3473-81. PubMed ID: 17146434
    [Abstract] [Full Text] [Related]

  • 8. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia.
    Kojima K, Konopleva M, McQueen T, O'Brien S, Plunkett W, Andreeff M.
    Blood; 2006 Aug 01; 108(3):993-1000. PubMed ID: 16543464
    [Abstract] [Full Text] [Related]

  • 9. Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53.
    Zhang S, Zhou L, Hong B, van den Heuvel AP, Prabhu VV, Warfel NA, Kline CL, Dicker DT, Kopelovich L, El-Deiry WS.
    Cancer Res; 2015 Sep 15; 75(18):3842-52. PubMed ID: 26294215
    [Abstract] [Full Text] [Related]

  • 10. MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity.
    Saha MN, Jiang H, Jayakar J, Reece D, Branch DR, Chang H.
    Cancer Biol Ther; 2010 Jun 01; 9(11):936-44. PubMed ID: 20418664
    [Abstract] [Full Text] [Related]

  • 11. MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function.
    Azmi AS, Aboukameel A, Banerjee S, Wang Z, Mohammad M, Wu J, Wang S, Yang D, Philip PA, Sarkar FH, Mohammad RM.
    Eur J Cancer; 2010 Apr 01; 46(6):1122-31. PubMed ID: 20156675
    [Abstract] [Full Text] [Related]

  • 12. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
    Kitagawa M, Aonuma M, Lee SH, Fukutake S, McCormick F.
    Oncogene; 2008 Sep 11; 27(40):5303-14. PubMed ID: 18521084
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of Mdm2 sensitizes human retinal pigment epithelial cells to apoptosis.
    Bhattacharya S, Ray RM, Chaum E, Johnson DA, Johnson LR.
    Invest Ophthalmol Vis Sci; 2011 May 01; 52(6):3368-80. PubMed ID: 21345989
    [Abstract] [Full Text] [Related]

  • 14. The MDM2 antagonist nutlin-3 sensitizes p53-null neuroblastoma cells to doxorubicin via E2F1 and TAp73.
    Peirce SK, Findley HW.
    Int J Oncol; 2009 May 01; 34(5):1395-402. PubMed ID: 19360352
    [Abstract] [Full Text] [Related]

  • 15. Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53.
    Cheok CF, Kua N, Kaldis P, Lane DP.
    Cell Death Differ; 2010 Sep 01; 17(9):1486-500. PubMed ID: 20203688
    [Abstract] [Full Text] [Related]

  • 16. The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer.
    Deben C, Wouters A, Op de Beeck K, van Den Bossche J, Jacobs J, Zwaenepoel K, Peeters M, Van Meerbeeck J, Lardon F, Rolfo C, Deschoolmeester V, Pauwels P.
    Oncotarget; 2015 Sep 08; 6(26):22666-79. PubMed ID: 26125230
    [Abstract] [Full Text] [Related]

  • 17. Blockade of Hsp90 by 17AAG antagonizes MDMX and synergizes with Nutlin to induce p53-mediated apoptosis in solid tumors.
    Vaseva AV, Yallowitz AR, Marchenko ND, Xu S, Moll UM.
    Cell Death Dis; 2011 May 12; 2(5):e156. PubMed ID: 21562588
    [Abstract] [Full Text] [Related]

  • 18. Mdm2 inhibition confers protection of p53-proficient cells from the cytotoxic effects of Wee1 inhibitors.
    Li Y, Saini P, Sriraman A, Dobbelstein M.
    Oncotarget; 2015 Oct 20; 6(32):32339-52. PubMed ID: 26431163
    [Abstract] [Full Text] [Related]

  • 19. MDM2 antagonist nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma.
    Tabe Y, Sebasigari D, Jin L, Rudelius M, Davies-Hill T, Miyake K, Miida T, Pittaluga S, Raffeld M.
    Clin Cancer Res; 2009 Feb 01; 15(3):933-42. PubMed ID: 19188164
    [Abstract] [Full Text] [Related]

  • 20. Inactivation of p53 signaling by p73 or PTEN ablation results in a transformed phenotype that remains susceptible to Nutlin-3 mediated apoptosis.
    Cipriano R, Patton JT, Mayo LD, Jackson MW.
    Cell Cycle; 2010 Apr 01; 9(7):1373-9. PubMed ID: 20305378
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.